Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Topical, Intravenous, Ophthalmic
01
Overview
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic and immunosuppressant originally isolated from the bacterium Streptomyces hygroscopicus. It acts primarily as an inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase that regulates cell growth, proliferation, and survival. Sirolimus is used to prevent organ rejection in patients receiving kidney transplants (typically in combination with other immunosuppressants) and to treat lymphangioleiomyomatosis (LAM), a rare lung disease. It is also available in topical formulations for certain dermatological conditions such as facial angiofibroma[2][3][4][5][7].
- Brand names
- RapamuneHyftorFyarroSupralimusCypher
- Other names
- rapamycin(-)-Rapamycinrapalimus
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus.